Advertisement

Reactions Weekly

, Volume 1753, Issue 1, pp 3–3 | Cite as

Japan PMDA's investigation results for May 2019

News item
  • 4 Downloads

References

  1. 1.
    Pharmaceuticals and Medical Devices Agency of Japan. Summary of investigation results: Dulaglutide (genetical recombination). Internet Document : [2 pages], 9 May 2019. Available from: URL: http://www.pmda.go.jp/english/safety/info-services/drugs/revision-of-precautions/0007.html
  2. 2.
    Pharmaceuticals and Medical Devices Agency of Japan. Summary of investigation results: sodium-glucose co-transporter 2 (SGLT2) inhibitors and combination products containing SGLT2 inhibitors. Internet Document : [3 pages], 9 May 2019. Available from: URL: http://www.pmda.go.jp/files/000229446.pdf
  3. 3.
    Pharmaceuticals and Medical Devices Agency of Japan. Summary of investigation results: Nivolumab (genetical recombination). Internet Document : [2 pages], 9 May 2019. Available from: URL: http://www.pmda.go.jp/files/000229447.pdf
  4. 4.
    Pharmaceuticals and Medical Devices Agency of Japan. Summary of investigation results: Lenvatinib mesilate. Internet Document : [1 page], 9 May 2019. Available from: URL: http://www.pmda.go.jp/files/000229448.pdf
  5. 5.
    Pharmaceuticals and Medical Devices Agency of Japan. Summary of investigation results: Influenza HA vaccine. Internet Document : [2 pages], 9 May 2019. Available from: URL: http://www.pmda.go.jp/files/000229449.pdf

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations